Drug Discovery Technology (1/3)



(Revised November 12, 2025)

Small Molecules Targeting RNA	 Method for measuring the binding affinity of RNA-targeting small molecules with in vivo relevance Excludes SPR, ITC, MST, AS-MS and SHAPE High through put in silico screening technology for RNA Efficient method for evaluating the three-dimensional structure of RNA
Drug discovery method aimed at covalent binders	 Fundamental technologies Evaluation methods for drug discovery
Cheminformatics	 Virtual screening methods that can screen a large-scale virtual library with high accuracy and speed Technology for highly accurate docking (SBDD) and simulation (LBDD) of peptide drug molecules
Screening and Synthesis Automation Technologies	• Operate throughout the day

Drug Discovery Technology (2/3)



(Revised November 12, 2025)

Peptide Therapeutics	 Identification of targets suitable for peptide drug discovery (e.g. undruggable targets that cannot be addressed with small molecules, such as protein-protein interaction) Synthesis technology to reduce the manufacturing costs of peptide drugs Formulation technology for efficient oral or nasal absorption of peptide drugs (e.g. solubilized formulations)
	 Technology to deliver antibodies into brain Discovery of novel target molecules for antibody drug development Chronic infectious diseases Central nervous system diseases Motor dysfunction diseases
Nucleic Acid Therapeutics	 Neurodegenerative diseases and motor dysfunction diseases for siRNA therapeutics Deliver siRNA into the brain and immune cells

Drug Discovery Technology (3/3)



(Revised August 7, 2025)

Pharmacokinetics	 In vitro assay for predicting human biliary clearance and enterohepatic circulation Drug transport and drug-drug interaction (DDI) risk prediction models using human P-gp/BCRP transgenic or knock-in animals Intracellular drug quantification for PK/PD and MoA insights Predict the risk of P-gp or BCRP inhibitory effects on drug absorption and disposition
Safety	 AI system to classify biochemical toxicity data as adverse or non-adverse In silico toxicity mechanism analysis system Predicting toxicity target organs using live animal image diagnosis (CT, MRI, etc.) In vitro model for ocular toxicity evaluation and mechanism analysis In vitro evaluation system to evaluate damage and regeneration of inner ear hair cells In vivo evaluation system for ototoxicity using ABR (Auditory Brainstem Response) Ames avoidance measures and prediction tools in nucleic acid analog drug discovery
Drug Discovery Platform Technologies	 Method for screening and optimizing enzyme activity based on substrate specificity of metabolite biosynthetic enzymes Bioinformatics techniques including enzyme sequence data Data-driven optimization for reproducible scale-up cultivation